Figure 4
Results of sensitivity analyses on efficacy rates. The efficacy of splenectomy, romiplostim, and rituximab varied by 50% below the base case analysis. Broken lines denote the results of the difference in the cost-effectiveness ratio in the base case analysis. (a) Difference in the cost-effectiveness ratios between sequences 1 and 2. (b) Difference in cost-effectiveness ratios between sequences 1 and 3.